Kexing Pharmaceutical Secures Rights for Chia Tai Tianqing’s Generic Ibrance in 11 Countries

Kexing Pharmaceutical (SHA: 688136), based in China, has entered into an international collaboration agreement with fellow Chinese firm Chia Tai Tianqing, securing commercialization rights for Chia Tai’s generic version of Pfizer’s Ibrance (palbociclib). This agreement encompasses an initial batch of 11 countries.

Palbociclib, recognized as the world’s first CDK4/6 inhibitor, received fast-track approval in the U.S. in 2015 and was granted marketing approval in China in 2018. Chia Tai Tianqing’s generic formulation was approved in March 2023 for use in first-line treatment of menopausal ER+/HER2- advanced breast cancer, either in combination with letrozole or fulvestrant for HR+/HER2- postmenopausal patients who have previously failed endocrine therapy. Furthermore, Chia Tai’s product was submitted for market approval in the U.S. in December of last year.- Flcube.com

Fineline Info & Tech